Technical Analysis for CLLS - Cellectis S.A.
|Grade||Last Price||% Change||Price Change|
CLLS closed down 2.27 percent on Friday, November 16, 2018, on 2.64 times normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
|Weak or Absent||Down||Down||Down|
|See historical CLLS trend table...|
|Date||Alert Name||Type||% Chg|
|Nov 16||New 52 Week Closing Low||Bearish||0.00%|
|Nov 16||Calm After Storm||Range Contraction||0.00%|
|Nov 16||Doji - Bullish?||Reversal||0.00%|
|Nov 16||Lower Bollinger Band Walk||Weakness||0.00%|
|Nov 16||New 52 Week Low||Weakness||0.00%|
|Nov 16||Stochastic Reached Oversold||Weakness||0.00%|
|Nov 16||Below Lower BB||Weakness||0.00%|
|Nov 16||Down 3 Days in a Row||Weakness||0.00%|
|Nov 16||Down 4 Days in a Row||Weakness||0.00%|
|Nov 16||Down 5 Days in a Row||Weakness||0.00%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Cellectis, a biopharmaceutical company, develops cancer products based on engineered T cells armed with a chimeric antigen receptor for the treatment of liquid and solid tumors. Its lead product candidate, UCART19, is an allogeneic engineered T cell product for the treatment of CD19 expressing hematologic malignancies that developed in chronic lymphocytic leukemia and acute lymphoblastic leukemia indications. The company's products also include hematopoietic tumors, such as UCART123 and UCART33 for acute myeloid leukemia indications, and UCART-BCMA and UCART38 for multiple myeloma indications, as well as solid tumors comprising UCART5T4 for various solid tumor indications and UCART-EgfrVIII for glioblastoma indications. In addition, it is focused on life sciences to build products based on genome engineering technologies in various fields and markets. Cellectis was founded in 1999 and is based in Paris, France.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more CLLS news...
|52 Week High||38.85|
|52 Week Low||21.29|
|200-Day Moving Average||29.2618|
|50-Day Moving Average||26.851|
|20-Day Moving Average||25.48|
|10-Day Moving Average||25.438|
|Average True Range||0.9467|
|Chandelier Exit (Long, 3 ATRs )||24.9899|
|Chandelier Exit (Short, 3 ATRs )||24.1301|
|Upper Bollinger Band||28.1781|
|Lower Bollinger Band||22.7819|
|Percent B (%b)||-0.14|
|MACD Signal Line||-0.4884|
|Market Cap||787.37 Million|
|Num Shares||35.8 Million|
|Price-to-Earnings (P/E) Ratio||-9.57|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||23.65|
|Resistance 3 (R3)||23.60||22.99||23.38|
|Resistance 2 (R2)||22.99||22.57||23.02||23.28|
|Resistance 1 (R1)||22.50||22.31||22.20||22.55||23.19|
|Support 1 (S1)||21.40||21.47||21.10||21.45||20.81|
|Support 2 (S2)||20.79||21.21||20.82||20.72|
|Support 3 (S3)||20.30||20.79||20.63|
|Support 4 (S4)||20.35|